Printer Friendly

Plasticell receives funding to produce red blood cell substitute from pluripotent stem cells.

M2 EQUITYBITES-April 13, 2017-Plasticell receives funding to produce red blood cell substitute from pluripotent stem cells

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Cell therapies developer Plasticell has received Biomedical Catalyst funding of over GBP920,000 from Innovate UK to create a red blood cell substitute for human clinical transfusion, the company revealed on Thursday.

Plasticell is working on the project in collaboration with stem cell scientists from the University of Edinburgh.

More than 90 million blood transfusions take place globally every year and, in order to meet rising demand, alternative sources to donor-derived blood are being investigated.

Securing a safer blood supply is vital as supply chains solely reliant on human donors are vulnerable to emerging diseases, and in developing countries there is a relatively high risk of transfusion-transmitted infection.

Plasticell executive chair, Yen Choo, explained that the company will use its own combinatorial stem cell screening technology, CombiCult, to improve the manufacturing process of using pluripotent stem cells to make red blood cells.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 13, 2017
Words:177
Previous Article:Axalta to Acquire NA Industrial Wood Coatings Business from Valspar for USD 420m.
Next Article:CTS launches Low Pass Filters in RLF family of products for wireless infrastructure applications.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters